- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05850728
Først i menneskelig undersøgelse af TLC-ART 101 (ACTU 2001)
Først i humant klinisk forsøg af en næste generation, langtidsvirkende injicerbar, antiretroviral kombinationsterapiplatform
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Denne undersøgelse er en prospektiv, åben-label, single-site, first-in-human undersøgelse af en langtidsvirkende, injicerbar antiretroviral terapiplatform med et farmakologisk styret adaptivt design til dosiseskalering, -deeskalering og undersøgelsens varighed . Undersøgelsen har to primære formål som følger:
- At karakterisere plasmakoncentration-tidsforløbet og farmakokinetikken (PK) af en enkelt dosis af lægemiddelstofferne i TLC-ART 101 (lopinavir, ritonavir og tenofovir) administreret ved subkutan injektion i lægemiddelkombinationen nanopartikel.
- At karakterisere sikkerheden og tolerabiliteten af en enkelt subkutan injektion af TLC-ART 101.
Der er 4 undersøgende mekanistiske mål (med relaterede endepunkter) som følger:
- At karakterisere lægemiddelstoffernes farmakokinetik i humane perifere mononukleære blodceller (PBMC'er)
- At karakterisere koncentrationerne af intracellulært TFV-diphosphat (den aktive del af TFV) i PBMC'er
- At undersøge om de farmakokinetiske parametre for de 3 lægemiddelstoffer er forskellige efter køn efter en enkelt dosis
- At sammenligne mononukleær celle i lymfoid væv versus PBMC-koncentrationer af lægemiddelstofferne i TLC-ART 101.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- UW Positve Research, Harborview Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- Sund med et BMI mellem 18,5 til 29,9 kg/m2
- Ikke-ryger eller tidligere ryger (defineret som ingen rygning eller ingen dampning eller ingen brug af tobaksstopprodukter i mere end 1 år)
- Personer af ethvert køn er berettigede, hvis de ellers opfylder alle andre adgangskriterier.
- Vurderet af undersøgelsespersonalet som værende i lav risiko for hiv-infektion og forpligtet til at opretholde adfærd i overensstemmelse med lav risiko for hiv-eksponering indtil efter at have afsluttet undersøgelsen.
- Villig og i stand til at give informeret samtykke.
- Hvis de deltager i seksuel aktivitet, der kan føre til graviditet, skal personer med reproduktionspotentiale acceptere at bruge specifikke former for prævention under hele undersøgelsen. Mindst to af følgende skal bruges gennem hele undersøgelsen:
- Kondom (mand eller kvinde)
- Diafragma eller cervikal hætte
- Kobberbaseret intrauterin enhed
- Vasektomi hos den mandlige partner
Bemærk: Udvalgte deltagere vil have et 72-timers indlæggelse på UW Medical Center.
Bemærk: Udvalgte deltagere vil gennemgå en lyskelymfeknudebiopsi.
Ekskluderingskriterier:
Bemærk, at følgende kriterier refererer til værdier fra screeningsbesøget
- Positiv HIV-1 fjerde generation antigen/antistof test
- Positiv hepatitis B overfladeantigentest
- Aktiv HCV-infektion Bemærk: Deltagere, der er positive for HCV-antistof, skal have et negativt HCV-RNA
- Enhver kronisk medicinsk tilstand, som efterforskeren vurderer som væsentlig (f.eks. astma, svære allergier, hypertension, hjertesygdomme, diabetes mellitus, hyperlipidæmi)
- Indtagelse af kronisk oral eller systemisk receptpligtig medicin (inklusive hormonimplantater eller hormonfrigivende intrauterine anordninger) inden for 30 dage før indrejsebesøget
- Indtagelse af kronisk oral eller systemisk ikke-receptpligtig medicin (håndkøb, håndkøb), som ikke sikkert kan stoppes
- Enhver klinisk signifikant abnorm værdi af CBC, kreatinin, AST, ALT, alkalisk fosfatase, total bilirubin
- PT/INR, PTT over den øvre grænse for normal
- U/A med enhver klinisk signifikant abnormitet
- Ethvert klinisk signifikant fund på EKG pr. lægegennemgang
- Urintoksikologisk screening positiv for ethvert ulovligt stof (bortset fra cannabis, hvis deltageren indvilliger i at stoppe brugen af cannabis i 14 dage før deltagelse i undersøgelsen og under undersøgelsens varighed, og det menes at være troværdigt i dette løfte efter udtalelse fra efterforskeren)
- BP > 140 systolisk eller > 90 diastolisk mmHg
- Kendt allergi/følsomhed eller enhver overfølsomhed over for LPV, RTV, TFV eller et af lipiderne i TLC-ART 101 (inklusive anafylaksi over for en COVID-19 mRNA-vaccine)
- Aktivt stof- eller alkoholbrug eller afhængighed eller psykiatrisk sygdom, der efter stedets efterforskers mening ville forstyrre overholdelse af studiekrav
- Akut eller alvorlig sygdom, der kræver systemisk behandling, antibiotika og/eller hospitalsindlæggelse inden for 90 dage før studiestart
- Ar eller tatoveringer på den centrale mave, der ville forstyrre administration af en subkutan injektion eller vurdering af det sted, hvor undersøgelsesmedicinen er planlagt til at blive administreret (inden for 1 tomme fra navlen)
- Diagnose af syfilis, gonoré eller klamydia inden for det seneste år
- Personer, der er gravide, har til hensigt at blive gravide eller ammer
Yderligere eksklusionskriterier for deltagere, der skal gennemgå lymfeknudebiopsi
- Allergi over for lidocain eller ethvert beslægtet "-caine" lægemiddel
- Kroniske ar eller tatoveringer i begge lyskeområder, der kan forstyrre udførelsen af en lymfeknudebiopsi eller øge sandsynligheden for et dårligt kosmetisk resultat
- Angst eller enhver anden tilstand, der har stor sandsynlighed for at forstyrre den vellykkede udførelse af en lymfeknudebiopsi udført under lokalbedøvelse
- Enhver koagulopati eller tilstand, der ville øge risikoen for blødning
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: TLC-ART 101 Startdosering
Armene vil alle modtage nanopartikelsuspensionen af lopinavir, ritonavir og tenofovir (TLC-ART 101). Armene kaldes også kohorter. Den dosis, en deltager modtager, vil variere afhængigt af undersøgelsesresultaterne og tidspunktet for, hvornår de tilmelder sig undersøgelsen. Den indledende dosis administreret til 4 deltagere vil indeholde: lopinavir 15,6 mg, ritonavir 4,2 mg og tenofovir 9,15 mg i 1,5 ml af formuleringen Hvis startdosis er passende, vil yderligere 8 deltagere blive tilmeldt Arm 1, for en samlet undersøgelsesstørrelse på 12 deltagere. |
TLC-ART 101 indeholder lopinavir, ritonavir og tenofovir i en kombination af nanopartikelsuspension
|
|
Eksperimentel: TLC-ART 101 Dosering 2A
I det scenarie, hvor doseringen i arm 1 producerer utilstrækkelig farmakokinetik (PK), vil dosis blive øget 2 gange i arm 2A og administreret til 4 deltagere. Hvis arm 2A viser ideelle PK-parametre, og yderligere 8 deltagere vil blive tilmeldt denne arm, for en samlet undersøgelsesstørrelse på 16 deltagere. |
TLC-ART 101 indeholder lopinavir, ritonavir og tenofovir i en kombination af nanopartikelsuspension
|
|
Eksperimentel: TLC-ART 101 Dosering 2B
I scenariet, hvor doseringen i arm 1 producerer for høje lægemiddelniveauer, vil doseringen blive reduceret med op til 2-5 gange (2-5 gange faldende dosis) og administreret til 4 deltagere. Hvis arm 2B viser ideelle PK-parametre, og yderligere 8 deltagere vil blive tilmeldt denne arm, for en samlet undersøgelsesstørrelse på 16 deltagere. |
TLC-ART 101 indeholder lopinavir, ritonavir og tenofovir i en kombination af nanopartikelsuspension
|
|
Eksperimentel: TLC-ART 101 Dosering 3A
I det scenarie, hvor doseringen i Arm 2A producerer utilstrækkelige lægemiddelniveauer, kan dosis øges yderligere 2 gange fra Arm 2A-dosis (4x total dosisstigning) og administreres til yderligere 4 deltagere. Hvis arm 3A viser ideelle PK-parametre, og yderligere 4 deltagere vil blive tilmeldt denne arm, for en samlet undersøgelsesstørrelse på 16 deltagere |
TLC-ART 101 indeholder lopinavir, ritonavir og tenofovir i en kombination af nanopartikelsuspension
|
|
Eksperimentel: TLC-ART 101 Dosering 3B
I det scenarie, hvor doseringen i Arm 2B producerer for høje lægemiddelniveauer, kan doseringen yderligere reduceres med op til 2-5 gange fra Arm 2B dosering (4-10x dosisreduktion) og administreres til 4 deltagere. Hvis arm 3B viser ideelle PK-parametre, og yderligere 4 deltagere vil blive tilmeldt denne arm, for en samlet undersøgelsesstørrelse på 16 deltagere |
TLC-ART 101 indeholder lopinavir, ritonavir og tenofovir i en kombination af nanopartikelsuspension
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Co-primary Pharmacokinetic Outcome: Peak TLC-101 Drug Substance Concentrations (Cmax) in Plasma
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
The maximum drug substance plasma concentrations of lopinavir, ritonavir, and tenofovir obtained following a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Time to Maximum TLC-101 Concentration (Tmax) of Drug Substances in Plasma
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Time (hours) to reach the maximum concentrations of lopinavir, ritonavir, and tenofovir after a single administration of TLC-ART-101.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Total TLC-101 Drug Substance Exposure (Area Under the Curve or AUC) in Plasma
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Area under the curve of plasma concentrations of lopinavir, ritonavir, and tenofovir over the study timecourse after a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Estimated Half-life (T 1/2) of TLC-101 Drug Substance Concentrations in Plasma
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
The apparent terminal half-life of drug substance plasma concentrations of lopinavir, ritonavir, and tenofovir after a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
The apparent terminal half-life T1/2,z was computed by regression on at least 3 detectable points if Tlast was at 57 or 64 days (end of study) or 2 detected and the first undetectable if Tlast < 57 or 64 days; detectable timepoints following undetectable plasma levels were excluded from the T1/2 estimation.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Primary Safety Outcome
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Treatment emergent adverse events related to TLC-ART 101 as graded by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (Corrected Version 2.1 - July 2017).
Only related injection site reactions (ISRs) or other related systemic events are reported here.
Comprehensive adverse events, related and unrelated, are reported in the Adverse Event section.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sekundært farmakokinetisk resultat: Sammenligning af TLC-101 lægemiddelstofkoncentrationer i mononukleære celler i perifert blod sammenlignet med plasmaniveauer
Tidsramme: varighed af opfølgning i dage for denne undersøgelse (forventet at være 57 dage pr. deltager)
|
At karakterisere koncentrationerne af de tre lægemiddelstoffer i humane perifere mononukleære blodceller fra de samme blodprøver som plasmaanalyser
|
varighed af opfølgning i dage for denne undersøgelse (forventet at være 57 dage pr. deltager)
|
|
Sekundært resultat af tenofovir aktiv lægemiddeldel
Tidsramme: 57 dages studieopfølgning
|
At karakterisere koncentrationerne af intracellulært tenofovir-diphosphat (den aktive del af TFV) i mononukleære celler i perifert blod
|
57 dages studieopfølgning
|
|
TLC-101-koncentrationer i lymfoidt væv
Tidsramme: 57 dages studieopfølgning
|
At sammenligne mononukleære celler i lymfoidvæv versus mononukleære cellekoncentrationer i perifert blod af lægemiddelstofferne i TLC-ART 101
|
57 dages studieopfølgning
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic Outcome: Estimated Duration of TLC-101 Drug Substance Detection in Peripheral Blood Mononuclear Cells (PBMCs)
Tidsramme: Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Concentrations of the three drug substances in human peripheral blood mononuclear cells from the same blood samples as plasma analyses Duration of drug detection in PBMCs includes the T(ALLQ), or the time in days for which drug concentrations remained persistently above the lower limit of quantification (LLQ), with detectable levels that occurred following LLQ or undetectable values censored; and Tlast, or the time in days until the last quantifiable (≥LLQ) time point regardless of intermediate undetectable/unquantifiable values. For T(ALLQ), no censoring was applied until 24hrs after administration as the drug was absorbed from the injection site. Concentrations of drugs within PBMCs often showed 2 curves, and sometimes with undetectable values between, hence presentation of TALLQ and Tlast to fully characterize the drug timecourse. TALLQ represents the more traditional clinical PK analysis wherein all values after the first LLQ are censored, and Tlast includes all timepoints. |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: AUC (Area Under the Curve) of TLC-ART 101 Drug Substances in Peripheral Blood Mononuclear Cells (PBMCs)
Tidsramme: Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Total exposure of the three drug substances in human peripheral blood mononuclear cells is measured from the same blood samples as plasma analyses. Total exposure to TLC-ART 101 drug components in PBMCs is represented by the area under the curve (AUC). The AUC is presented from Time 0 through the T(ALLQ), representing total exposure throughout the time point (Endpoint #6) through which the drug has always remained above the lower limit of quantification (LLQ). |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: Duration of Intracellular Tenofovir Active Drug Moiety Detection
Tidsramme: Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Duration of detection of intracellular tenofovir-diphosphate (the active moiety of TFV, or TFV-DP) in peripheral blood mononuclear cells. Duration of TFV-DP in PBMCs includes the T(ALLQ), or the time in days for which drug concentrations remained persistently above the lower limit of quantification (LLQ), with detectable levels that occurred following LLQ or undetectable values censored; and Tlast, or the time in days until the last quantifiable (≥LLQ) time point regardless of intermediate undetectable/unquantifiable values. For T(ALLQ), no censoring was applied until 24hrs after administration as the drug was absorbed from the injection site. Concentrations of drugs within PBMCs often showed 2 curves, and sometimes with undetectable values between, hence presentation of TALLQ and Tlast to fully characterize the drug timecourse. TALLQ represents the more traditional clinical PK analysis wherein all values after the first LLQ are censored, and Tlast includes all timepoints. |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: AUC (Area Under the Curve) of the Intracellular Tenofovir Active Drug Moiety in Peripheral Blood Mononuclear Cells (PBMCs)
Tidsramme: Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Total exposure to tenofovir diphosphate (TFV-DP) in PBMCs is represented by the area under the curve (AUC).
The AUC is presented from Time 0 through the T(ALLQ), representing total exposure throughout the time point (Endpoint #8) through which TFV-DP has always remained above the lower limit of quantification (LLQ).
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
TLC-101 Concentrations in Lymphoid Tissues
Tidsramme: 24hrs (Day 1) after TLC-ART 101 administration
|
Concentration of lymphoid tissue mononuclear cell (LMNC) drug substances in TLC-ART 101 by measuring concentrations of lopinavir, ritonavir, and tenofovir in lymph node mononuclear cells retrieved from inguinal lymph node excision at 24 hours after receipt of TLC-ART 101.
|
24hrs (Day 1) after TLC-ART 101 administration
|
|
Ratio of TLC-ART 101 Drugs in Lymph Node Mononuclear Cells (LNMC) to Peripheral Blood Mononuclear Cells (PBMC)
Tidsramme: 24hrs (Day 1) after TLC-ART 101 administration
|
This is the ratio of the LNMC to PBMC concentration at 24hrs after TLC-ART 101 administration within the same 2 individuals
|
24hrs (Day 1) after TLC-ART 101 administration
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Rachel A Bender Ignacio, MD MPH, University of Washington
Publikationer og nyttige links
Generelle publikationer
- Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.
- Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses. 2015 Jan;31(1):107-14. doi: 10.1089/aid.2014.0210.
- McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. J Pharm Sci. 2018 Jul;107(7):1787-1790. doi: 10.1016/j.xphs.2018.03.005. Epub 2018 Mar 13.
- Kraft JC, Treuting PM, Ho RJY. Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. J Drug Target. 2018 Jun-Jul;26(5-6):494-504. doi: 10.1080/1061186X.2018.1433681. Epub 2018 Feb 12.
- Perazzolo S, Shireman LM, McConnachie LA, Koehn J, Kinman L, Lee W, Lane S, Collier AC, Shen DD, Ho RJY. Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101. J Pharm Sci. 2020 May;109(5):1789-1801. doi: 10.1016/j.xphs.2020.01.016. Epub 2020 Jan 29.
- Perazzolo S, Shireman LM, Shen DD, Ho RJY. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture. J Pharm Sci. 2022 Feb;111(2):529-541. doi: 10.1016/j.xphs.2021.10.007. Epub 2021 Oct 19.
- Perazzolo S, Shen DD, Ho RJY. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles. J Pharm Sci. 2022 Mar;111(3):825-837. doi: 10.1016/j.xphs.2021.10.009. Epub 2021 Oct 19.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Blodbårne infektioner
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i immunsystemet
- Infektioner
- RNA-virusinfektioner
- Virussygdomme
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Langsomme virussygdomme
- HIV-infektioner
- Erhvervet immundefektsyndrom
Andre undersøgelses-id-numre
- STUDY00007490
- U01AI148055 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .